drugset / Trial / NCT07213674
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
Timeline
- Start
- 2025-11-28
- Primary completion
- 2030-01-07
- Completion
- 2032-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | — | Oral |
| Comparator | Cabazitaxel | Other / unclassified | — | Intravenous |
| Comparator | Docetaxel | Small molecule | — | Intravenous |
| Subject | Xaluritamig | Unknown | — | Intravenous |